William Blair analyst Ryan Daniels has maintained their bullish stance on TMDX stock, giving a Buy rating today.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ryan Daniels has given his Buy rating due to a combination of factors related to TransMedics’ growth outlook and execution. After meetings with senior leadership, he came away more confident that the company is positioned as a high-conviction alpha idea for 2026, supported by internal flight-tracking analysis that indicates first-quarter procedure volumes are in line with market expectations.
Daniels also highlights upcoming clinical milestones for the next-generation heart and lung platforms, where positive early experience in trials could accelerate adoption and revenue in the second half of the year. In addition, he sees substantial upside from international expansion, noting that Europe can effectively double the company’s addressable market and may have an even greater need for its technology, reinforcing the long-term growth case behind his Buy recommendation.
Daniels covers the Healthcare sector, focusing on stocks such as TransMedics Group, Healthcare Services, and HealthStream. According to TipRanks, Daniels has an average return of -2.9% and a 34.15% success rate on recommended stocks.
In another report released today, TipRanks – OpenAI also reiterated a Buy rating on the stock with a $140.00 price target.